ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.01
-1.49%
US Tech 100
18,944.00
-3.70%
S&P 500
5,614.56
-2.70%
US Dollar vs CAD
1.44373
0.46%
Bitcoin
79,370.26
-1.51%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Anavex Life Sciences Corporation (AVXL) Share Price

Anavex Life Sciences Corporation

Anavex Life Sciences Corporation (AVXL)

NASDAQ
8.99
0.32
(3.69%)
At close: March 10 3:00PM
Delayed by 15 minutes
8.99
0.00
( 0.00% )
After Hours: 3:44PM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
8.99
Bid
8.98
Ask
8.99
Volume
903,730
8.41 Day's Range 9.2476
3.25 52 Week Range 14.4405
Market Cap
764.727M
Previous Close
8.67
Open
8.46
Last Trade
2
@
8.9899
Last Trade Time
16:01:54
Financial Volume
US$ 8,028,416
VWAP
8.8836
Average Volume (3m)
1,730,302
Shares Outstanding
85,064,199
Dividend Yield
-
PE Ratio
-17.78
Earnings Per Share (EPS)
-0.51
Revenue
-
Net Profit
-43M

About Anavex Life Sciences Corporation

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are u... Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.anavex.com
Headquarters
Carson City, Nevada, USA
Founded
-
Anavex Life Sciences Corporation is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker AVXL. The last closing price for Anavex Life Sciences was US$8.67. Over the last year, Anavex Life Sciences shares have traded in a share price range of US$ 3.25 to US$ 14.4405.

Anavex Life Sciences currently has 85,064,199 shares outstanding. The market capitalization of Anavex Life Sciences is US$737.51 million. Anavex Life Sciences has a price to earnings ratio (PE ratio) of -17.78.

Ask ADVFN Intelligence (AI)

Anavex Life Sciences (AVXL) Options Flow Summary

AVXL Options Flow

Overall Flow

Bearish

Net Premium

-11k

Calls / Puts

100.00%

Buys / Sells

100.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

AVXL Latest News

More News

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
February 12 2025
AVXL (3.69%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
January 17 2025
AVXL (3.69%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
December 23 2024
AVXL (3.69%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
11.0212.79799247187.978.99997.8710094758.47204493CS
40.343.930635838158.659.20237.7110482048.38034072CS
120.485.640423031738.5114.44057.71173030210.28689928CS
263.8474.56310679615.1514.44054.930113982338.98784297CS
523.5665.5616942915.4314.44053.2512736597.10110565CS
156-1.91-17.522935779810.915.243.2512038328.38234254CS
2605.29142.9729729733.731.52.2134947910.72444833CS

AVXL - Frequently Asked Questions (FAQ)

What is the current Anavex Life Sciences share price?
The current share price of Anavex Life Sciences is US$ 8.99
How many Anavex Life Sciences shares are in issue?
Anavex Life Sciences has 85,064,199 shares in issue
What is the market cap of Anavex Life Sciences?
The market capitalisation of Anavex Life Sciences is USD 737.51M
What is the 1 year trading range for Anavex Life Sciences share price?
Anavex Life Sciences has traded in the range of US$ 3.25 to US$ 14.4405 during the past year
What is the PE ratio of Anavex Life Sciences?
The price to earnings ratio of Anavex Life Sciences is -17.78
What is the reporting currency for Anavex Life Sciences?
Anavex Life Sciences reports financial results in USD
What is the latest annual profit for Anavex Life Sciences?
The latest annual profit of Anavex Life Sciences is USD -43M
What is the registered address of Anavex Life Sciences?
The registered address for Anavex Life Sciences is 701 S CARSON ST, STE 200, CARSON CITY, NEVADA, 89701
What is the Anavex Life Sciences website address?
The website address for Anavex Life Sciences is www.anavex.com
Which industry sector does Anavex Life Sciences operate in?
Anavex Life Sciences operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TNONTenon Medical Inc
US$ 1.841
(47.28%)
2.7M
BKYIBIO key International Inc
US$ 1.39
(26.36%)
882.32k
CUTRCutera Inc
US$ 0.1567
(21.95%)
14.92M
LFMDLifeMD Inc
US$ 5.133
(20.21%)
194.36k
SNOASonoma Pharmaceuticals Inc
US$ 3.32
(19.00%)
2.79M
MYPSPLAYSTUDIOS Inc
US$ 1.22
(-18.67%)
10.42k
BLBXBlackBoxStocks Inc
US$ 2.65
(-13.40%)
8.35k
BDRXBiodexa Pharmaceuticals PLC
US$ 2.49
(-12.63%)
106.41k
RDGTRidgetech Inc
US$ 0.7009
(-12.39%)
3.3k
BONBon Natural Life Ltd
US$ 1.02
(-10.40%)
6.57k
CUTRCutera Inc
US$ 0.1556
(21.09%)
14.94M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 7.35
(-0.41%)
4.69M
NVDANVIDIA Corporation
US$ 106.94
(-0.04%)
3.8M
STSSSharps Technology Inc
US$ 0.4185
(-4.89%)
3.44M
TSLATesla Inc
US$ 221.55
(-0.27%)
3.16M

AVXL Discussion

View Posts
Hoskuld Hoskuld 6 minutes ago
This is probably not the right forum, but the deficit problem is solvable. We have to attack it the same way we did rebuilding Europe with the Marshal Plan post-WW2: we tax ourselves at a high rate and pay it down. The annual deficit is something that ballooned from 350b at the end of the Obama administration to $2T under Trump (average,. not peak.) Trump is no deficit-slayer.

We should cut the fat out of the budget. That fat is not in foreign aid or food stamps - anything found there is minimal. The big fat is in the defense budget. But defense is important, and most of us think the waste there (within reason) is OK. Still, the only way to close the budget is to tax. We had a balanced budget as recently as the late 90s under Clinton (with a Republican-controlled house of reps that was acting in the best interests of the country.) Then we cut, cut, and cut taxes more (and started 3 wars at the same time) and the deficit ballooned in step-wise increases - under Bush...then was chipped away at for 8 years under Obama...then ballooned massively under Trump. The lesson should be: we have to pay for our security, health, and infrastructure. There are no free rides.

We Americans need to band together and take up the challenge of paying down our debt and building again. This is what it means to be good stewards of a great legacy. Greed has clouded our minds and we need to clear them.
👍️0
williamssc williamssc 10 minutes ago
True a lot of retirees in Florida. I have read there's also a lot of fraud with doctors billing.
👍️ 1 👎️ 1 👺 1
boi568 boi568 16 minutes ago
"DOGE," a collection of youngsters recruited by Elon Musk, is neither a government department lawfully empowered to impound Congressionally appropriated activities, nor effective in rooting out "waste" in these programs. Musk just wants to call programs he doesn't agree with "waste" so he can unconstitutionally kill them.
👍️ 2 👺 2 💯 1
williamssc williamssc 19 minutes ago
Probably so. Like me in retirement I don't make what I did as a working engineer. Retirement income replaced with social security and a pension if your so lucky. I'm one of the luck ones. My wife and I live like my parents did just enjoying life, freezing and canning and going to church. Living frugal. Our carbon foot print is a baby step. lol
👍️ 2
falconer66a falconer66a 21 minutes ago
Medicare Costs and Blarcamesine
And the cheapest solution potentially available, blacarsamine, [to treat Alzheimer's] will benefit if there was belt-tightening.
As we know, increasing numbers of the elderly are succumbing to Alzheimer's disease each year. They all will need treatment; which in the U.S will involve Medicare or other government funding sources.

The existing Alzheimer's treatments, the FDA-approved monoclonal antibody drugs, Leqembi, etc., are extremely expensive. Blarcamesine won't be. The cost difference will be a powerful driver for blarcamesine approval and utilization; across the Western world. Government medical insurance agencies save lots and lots of money. Patients do, too. And, blarcamesine is far easier and convenient to take, a single pill a day. No need to be taken to a radiology center to get periodic brain scans to check for brain hemorrhaging or shrinkage. Most importantly, blarcamesine will exhibit far better treatment outcomes.

Blarcamesine, and Anavex (and its shareholders) will win.
🎯 1 👍️ 5 💯 1
boi568 boi568 23 minutes ago
I would expect a lot of payments to go to such a large state known for the size of its retired population.
👍️ 2 💯 1
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 23 minutes ago
Of course they are not talking about it. You do financial stuff; do the math.

Here's "the math". The USA cannot afford to keep borrowing 33 cents of every dollar spent, $2 Trillion plus a year, without a financial reckoning that will make Medicare funding a minor issue. The country is not in a recession, the budget should be balanced not at record deficits. And increasing taxes 50% would crater the economy. So the only solution is to cut out the massive waste and fraud and featherbedding that DOGE is finding.
🎯 2 👍️ 4 👎️ 1 👺 1
mike_dotcom mike_dotcom 26 minutes ago
Rick Scott could probably tell you all about it.
👍️0
kund kund 28 minutes ago
WGT is talking about Medicare and Anavex—it's like putting the cart before the horse. The moron CEO isn’t even talking to the FDA. He first needs to schedule a Type B meeting with the agency and come up with a plan for NDA filing. Even if he starts today, it will take more than a year for an FDA decision. So lay down your pipe and get back to reality.
👎️ 1 👺 1
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 31 minutes ago
Correct. Medicare advantage is not government Medicare. People should avoid these plans which look good up front but provide less at their core.

With "Advantage" plans, the insurer decides if you get treatment. So if you have cancer and are 85, they could say it is not cost-effective to treat you, go die. Kind of like what the original Obamacare was about with Dr. Ezekiel Emmanuel. Death panels doing economics analysis.

Get supplementary medicare insurance where you and the doctor make the decision on treatment, not an economist.
👍️ 3
Hoskuld Hoskuld 34 minutes ago
2-73 should be covered by Medicare part D - and part D premiums are based on income. Do you agree?
👍️ 1 👎️ 1 👺 1 😁 1
williamssc williamssc 35 minutes ago
It's a big problem that needs solved perhaps better software to catch it. A lot of payments seem to go to Florida.
👎️ 1 👺 1
boi568 boi568 37 minutes ago
$800 billion?
👍️0
LakeshoreLeo1953 LakeshoreLeo1953 38 minutes ago
You ARE kidding about Medicare premium pricing?
Do just a bit of investigating.
Sight unseen I would take your premium.
👍️0
Hoskuld Hoskuld 38 minutes ago
Of course, the big value driver is product approval.
👍️ 1
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 38 minutes ago
more silliness

Yes, and if the Medicare program isn't funded as well in the future there would be no getting around the shrinking of the AD market in the United States.

Bedtime stories donkeys use to scare their parents.
🏆️ 1 👍️ 2 👎️ 1 👺 1 🤣 1
williamssc williamssc 38 minutes ago
I hope they cut out fraudulent payments BEFORE they go out. Wouldn't that be something. Medicare loses Billions to fraud.
🎯 1 👍️ 2 👎️ 1 👺 1
boi568 boi568 40 minutes ago
Of course they are not talking about it. You do financial stuff; do the math.

"[N]o one is talking about cutting Medicare, just the fraud so there is enough money for real patients."
👍️ 1 👎️ 1 🙄 1
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 42 minutes ago
Incorrect and silly statement

Yes, investors here should keep an eye on the political threat to Medicare and Medicaid, since those are critical insurers in the event of FDA approval of blarcamesine and an ultimate source of a great deal of revenue for us in the U.S. Alzheimer's market.

There is no threat to Medicare, in fact rooting out the fraud and corruption is necessary to protect them. And the cheapest solution potentially available, blacarsamine, will benefit if there was belt-tightening.
🎯 1 👍️ 1 👎️ 1 👺 1 🤣 1
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 45 minutes ago
you're trying too hard 😄

The only thing that would affect AVXL is the EMA approval. Period. Tariffs mean nothing for a business with no revenues, working on a product that is a medical need, not a discretionary purchase. And no one is talking about cutting Medicare, just the fraud so there is enough money for real patients.
🎯 1 👍️ 1 👎️ 1 👺 1
dia76ca dia76ca 50 minutes ago
AVXL can certainly be a Safe Haven Investment. But it will be affected by the general market. Volumes should be much higher. The share price should already be multiples of the current price!
However there are powerful catalysts in coming months.
1. More long term trial (OLE) information.
2. Anavex 3-71 phase 2b Schizophrenia trial results.
3. Partnerships for Europe, the UK, Canada and Australia and Asia
4. European approval for blarcamesine.
5. FDA discussions leading to priority review.
There is a worldwide need for blarcamesine and Anavex 3-71. That need will only increase with time.
Follow the science!
👍️ 3
williamssc williamssc 53 minutes ago
Medicare premiums are the same for the "less wealthy". Many may not know this but government premiums have risen $30.00 a month for everyone on medicare just to pay the "mab" costs. I'm hoping when Blarcamesine is approved costs will revert back. Hope springs eternal. Praying for a good outcome for medicare folks and everyone else.
👍️ 2
plexrec plexrec 1 hour ago
Jonjones--"You never know."--long time no hear from you---good to see you are still around--our day coming soon !!!!
👍️ 1
Hoskuld Hoskuld 1 hour ago
Since you are here on a stock message board, you are probably wealthy. But many are not - and that is when the government and insurance steps in. Undermine that system and the upside lowers.
👍️ 1 💯 1
poguemahone poguemahone 1 hour ago
Cool the engines….one day does not a trend make.
👍️0
falconer66a falconer66a 1 hour ago
AVXL as a Safe Haven Investment?

Ok, how might a typical, general stock investor perceive things when the stock indices all continue to descend, but the AVXL share price continues to ascend?

Stock investors do their D.D., due diligence (which is, really, their "determining diligence"). What will potential new AVXL investors find when they search around for the reasons the AVXL share price is rising, contrary to the declining trends of the stock indices?

Will potential new AVXL buyers see that Anavex science is becoming validated, and large drug sales will begin, especially when the European Medicines Agency approves blarcamesine for Alzheimer's?

Shortly, will Anavex Life Sciences Corp be a safe haven investment in an otherwise declining equity market? Let's watch.
👍️ 7
georgejjl georgejjl 2 hours ago
Expect over 1 million AVXL shares to be bought today!!!

Good luck and GOD bless,
👍️0
boi568 boi568 2 hours ago
Medicare advantage is not government Medicare. People should avoid these plans which look good up front but provide less at their core. Medicare is run much more leanly than for-profit Medicare advantage plans. However, they all would suffer if Medicare is cut, including any coverage of AD prescriptions.
👍️ 4
boi568 boi568 2 hours ago
Yes, and if the Medicare program isn't funded as well in the future there would be no getting around the shrinking of the AD market in the United States.
👍️ 1
rx7171 rx7171 2 hours ago
Congress created the Advantage option for Medicare at the behest of the insurance industry to get a chance to make profits from Medicare recipients.
They make profits by minimizing care through procedural run arounds and paperwork.

I ‘m very happy with my regular Medicare since it is not driven by a profit motive.
No run around getting coverage when needed.
🎯 1 👍️ 5
aredrooster aredrooster 2 hours ago
Anavex news... like a box of chocolates ... and so on.
👍️ 2 😃 1
georgejjl georgejjl 2 hours ago
How many people expect news regarding Anavex this week???

Good luck and GOD bless,
👍️0
williamssc williamssc 2 hours ago
Elderly buy a lot of lottery tickets:)
👎️ 1 👺 1
Investor2014 Investor2014 2 hours ago
Cancer indications - yes!
👍️0
williamssc williamssc 2 hours ago
Medicare advantage has been eroding for years now, they are paying less and less while raising the out of pocket and now most want you to get a referral. Jerking old people around is what they do best. Congress needs to kick these insurers in the keester.
👍️ 3
LakeshoreLeo1953 LakeshoreLeo1953 2 hours ago
“List Price” of Rx for the retired is a fallacy.
However, $10K/yr premiums and 3-5K deductible is a reality per couple.
Factor in Dental and Vision…you best be prepared for retirement.

Of course those able to gamble in pre revenue bio shouldn’t worry…..
👍️ 1 👎️ 1 👺 1
Steady_T Steady_T 2 hours ago
Drugs are covered by Part D plans. Every Medicare recipient chooses which plan they want to enroll in. Each plan has different drugs that it will pay for and those are chosen by the private plans.
👍️ 1
williamssc williamssc 3 hours ago
I like most elderly on medicare pay for our meds. My supplemental prescription plan helps but I still pick up my portion. These plans are not cheap and on top of monthly medicare costs. I don't know anyone getting anything cheap.
👍️ 5
Jonjones325 Jonjones325 3 hours ago
Just doing a little AI searching. Companies can and have been approved after clock stop 1.

You never know. 
👍️ 8 😃 1
Hoskuld Hoskuld 3 hours ago
If approved, then 2-73 will be a winner.
👍️ 4
rx7171 rx7171 3 hours ago
Here is the published scientific article.
https://onlinelibrary.wiley.com/doi/10.1111/acel.13037
👍️ 2
Steady_T Steady_T 3 hours ago
Why do you care what I believe? I state my positions on the various Anavex issues. Agree or disagree as you wish. My opinion of the value of other posters is a personal evaluation. I like to keep it that way most of the time. Well, unless there is something so silly I can't help but make fun of it.
👍️0
LakeshoreLeo1953 LakeshoreLeo1953 3 hours ago
The flip side might be…

Hold 300K shares through $30
and back to $3 because AVXL
“has the goods” and WGT. Or one could just take the Sat phone and go fight forest fires.

Not verifying either scenario, but I think I can figure out which has done better.

There is always tomorrow, News, and WAGs about performance. This MB does not lack for assurances.
👍️ 1 👎️ 2 👺 1
boi568 boi568 3 hours ago
Yes, investors here should keep an eye on the political threat to Medicare and Medicaid, since those are critical insurers in the event of FDA approval of blarcamesine and an ultimate source of a great deal of revenue for us in the U.S. Alzheimer's market.
👍️ 1 👎️ 1 🤓 1
Lacey1 Lacey1 3 hours ago
The effective and inexpensive will rise to the top in the new environment.
👍️ 5 😃 1
Hoskuld Hoskuld 4 hours ago
Not entirely true because public companies all share the same macro environment. Self-infliected economic distress impacts all companies. But, yes, Anavex does not sell imported steel or aluminum or lumber or oil etc. And maybe the fact that their CEO is German and is fluent in Italian will be a major asset during the MAA process. In the USA, medicare and medicaid pay for a lot of medications - especially for the elderly - so cutting the legs from under those programs could be a problem for drug companies generally and for Anavex specifically.
👍️ 1 👎️ 2 👺 2 💯 1
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 4 hours ago
pre-revenue bios unaffected by tariff wars.
👍️ 2
Hoskuld Hoskuld 4 hours ago
Approval is not imminent, nor is it certain (although I think it is probable.) Anavex simply is not subject to all of the same market forces that much of the market is.

The next value driver will be OLE presentation (April). Then Clock Stop One info (May-June). Then 3-71 top line readout in July. Maybe Anavex gets a partner, too, at some point (wildcard.)
👍️ 2 👎️ 1 👺 1 😃 2 🧌 1 🧟 1
georgejjl georgejjl 5 hours ago
Do you expect NEWS regarding AVXL soon???

Good luck and GOD bless,
👍️ 1
aredrooster aredrooster 5 hours ago
Perhaps some short covering soon?
👍️ 3

Your Recent History

NASDAQ
AVXL
Anavex Life Sciences
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads